European CHMP recommends approval of licence extension of esketamine (Spravato)
The licence extension is for treatment of adults with a moderate to severe episode of major depressive disorder, as acute short-term treatment in conjunction with oral antidepressant therapy, for the rapid reduction of depressive symptoms, which constitute a psychiatric emergency
Source:
European Medicines Agency